Template:Antidepressants: Difference between revisions

Browse history interactively ← Previous editContent deleted Content addedVisual WikitextInline

Revision as of 20:49, 9 May 2017 view source88.1.212.139 (talk)No edit summary← Previous edit		Latest revision as of 08:47, 30 September 2023 view source Yellow whisper (talk \| contribs)18 editsmNo edit summary
(15 intermediate revisions by 10 users not shown)
Line 8:		Line 8:
	\| state1 = uncollapsed		\| state1 = uncollapsed
	\| group1 = Specific ]s and/or ]s		\| group1 = Specific ]s and/or ]s
	\| list1 = {{Navbox subgroup		\| list1 = {{Navbox\|subgroup

	\| group1 = ]s		\| group1 = {{abbrlink\|SSRIs\|Selective serotonin reuptake inhibitors}}
	\| list1 =		\| list1 =
	* ]		* ]
Line 21:		Line 21:
	* ]<sup>‡</sup>		* ]<sup>‡</sup>

	\| group2 = ]s		\| group2 = {{abbrlink\|SNRIs\|Serotonin–norepinephrine reuptake inhibitors}}
	\| list2 =		\| list2 =
	* ]		* ]
Line 29:		Line 29:
	* ]		* ]
	* ]		* ]
	* ]

	\| group3 = ]s		\| group3 = {{abbrlink\|NRIs\|Norepinephrine reuptake inhibitors}}
	\| list3 =		\| list3 =
	* ]		* ]
Line 37:		Line 36:
	* ]		* ]

	\| group4 = ]s		\| group4 = {{abbrlink\|NDRIs\|Norepinephrine–dopamine reuptake inhibitors}}
	\| list4 =		\| list4 =
	* ]<sup>‡</sup>		* ]<sup>‡</sup>
Line 43:		Line 42:
	* ]<sup>‡</sup>		* ]<sup>‡</sup>

	\| group5 = ]s		\| group5 = {{abbrlink\|NaSSAs\|Noradrenergic and specific serotonergic antidepressants}}
	\| list5 =		\| list5 =
	* ]		* ]
Line 49:		Line 48:
	* ]		* ]

	\| group6 = ]s		\| group6 = {{abbrlink\|SARIs\|Serotonin antagonist and reuptake inhibitors}}
	\| list6 =		\| list6 =
	* ]		* ]
Line 55:		Line 54:
	* ]		* ]

	\| group7 = ]s		\| group7 = {{abbrlink\|SMS\|Serotonin modulator and stimulators}}
	\| list7 =		\| list7 =
	* ]		* ]
Line 64:		Line 63:
	* ]		* ]
	* ]		* ]
			* ]
⚫	* ]<sup>†</sup>
			* ]
	* ]<sup>‡</sup>		* ]<sup>‡</sup>
			* ]
	* ]		* ]
			* ]
	* ]<sup>†</sup>
		⚫	* ]<sup>§</sup>
	* ]<sup>‡</sup>		* ]<sup>‡</sup>
	* ]<sup>‡</sup>		* ]<sup>‡</sup>
Line 80:		Line 82:
	\| state2 = uncollapsed		\| state2 = uncollapsed
	\| group2 = ] and ]s		\| group2 = ] and ]s
	\| list2 = {{Navbox subgroup		\| list2 = {{Navbox\|subgroup

	\| group1 = ]s		\| group1 = {{abbrlink\|TCAs\|Tricyclic antidepressants}}
	\| list1 =		\| list1 =
	* ]<sup>‡</sup>		* ]<sup>‡</sup>
	* ]<sup>#</sup>		* ]<sup>#</sup>
	* ]		* ]
		⚫	* ]
	* ]<sup>‡</sup>		* ]<sup>‡</sup>
	* ]<sup>#</sup>		* ]<sup>#</sup>
Line 112:		Line 115:
	* ]		* ]

	\| group2 = ]s		\| group2 = {{abbrlink\|TeCAs\|Tetracyclic antidepressants}}
	\| list2 =		\| list2 =

⚫	* ]
	* ]		* ]
	* ]		* ]
Line 128:		Line 131:
	\| state3 = uncollapsed		\| state3 = uncollapsed
	\| group3 = ]s		\| group3 = ]s
	\| list3 = {{Navbox subgroup		\| list3 = {{Navbox\|subgroup

	\| group1 = Non-selective		\| group1 = Non-selective
Line 153:		Line 156:
	* ''Mixed:'' ]		* ''Mixed:'' ]

	\| group2 = MAO<sub>A</sub>-selective		\| group2 = {{abbrlink\|MAO<sub>A</sub>\|Monoamine oxidase A}}-selective
	\| list2 =		\| list2 =

Line 164:		Line 167:
	* ]		* ]

	\| group3 = MAO<sub>B</sub>-~~Selective~~		\| group3 = {{abbrlink\|MAO<sub>B</sub>\|Monoamine oxidase B}}-selective
	\| list3 =		\| list3 =
	* ''Irreversible:'' ]		* ''Irreversible:'' ]
Line 181:		Line 184:
	\| group5 = Miscellaneous		\| group5 = Miscellaneous
	\| list5 =		\| list5 =
	* ]		* ]
			* ] ]s (], ])
	* ]		* ]
	* ]		* ]
	* ]		* ]
	* ]		* ]

Latest revision as of 08:47, 30 September 2023

Antidepressants (N06A)

Specific reuptake inhibitors and/or receptor modulators

SSRIsTooltip Selective serotonin reuptake inhibitors	Citalopram Escitalopram Fluoxetine Fluvoxamine Indalpine Paroxetine Sertraline Zimelidine
SNRIsTooltip Serotonin–norepinephrine reuptake inhibitors	Desvenlafaxine Duloxetine Levomilnacipran Milnacipran Tofenacin Venlafaxine
NRIsTooltip Norepinephrine reuptake inhibitors	Atomoxetine Reboxetine Viloxazine
NDRIsTooltip Norepinephrine–dopamine reuptake inhibitors	Amineptine Bupropion Nomifensine
NaSSAsTooltip Noradrenergic and specific serotonergic antidepressants	Mianserin Mirtazapine Setiptiline
SARIsTooltip Serotonin antagonist and reuptake inhibitors	Etoperidone Nefazodone Trazodone
SMSTooltip Serotonin modulator and stimulators	Vilazodone Vortioxetine
Others	Agomelatine Amisulpride Dextromethorphan/bupropion Esketamine Etryptamine Gepirone Indeloxazine Flupentixol Ketamine Medifoxamine Metryptamine Oxaflozane Pivagabine Tandospirone Teniloxazine Tianeptine

Tricyclic and tetracyclic antidepressants

TCAsTooltip Tricyclic antidepressants	Amineptine Amitriptyline Amitriptylinoxide Amoxapine Butriptyline Clomipramine Demexiptiline Desipramine Dibenzepin Dimetacrine Dosulepin Doxepin Imipramine Imipraminoxide Iprindole Lofepramine Melitracen Metapramine Nitroxazepine Nortriptyline Noxiptiline Opipramol Pipofezine Propizepine Protriptyline Quinupramine Tianeptine Trimipramine
TeCAsTooltip Tetracyclic antidepressants	Maprotiline Mianserin Mirtazapine Setiptiline
Others	Tiazesim

Monoamine oxidase inhibitors

Non-selective

Reversible: Caroxazone

Mixed: Bifemelane

MAO_ATooltip Monoamine oxidase A-selective

MAO_BTooltip Monoamine oxidase B-selective

Irreversible: Selegiline

Adjunctive therapies
Atypical antipsychotics (aripiprazole, brexpiprazole, lurasidone, olanzapine, quetiapine, risperidone) Buspirone Lithium (lithium carbonate, lithium citrate) Thyroid hormones (triiodothyronine (T₃), levothyroxine (T₄))

Miscellaneous
Ademetionine (SAMe) GABAkine neurosteroids (brexanolone, zuranolone) Hypericum perforatum (St. John's Wort) Oxitriptan (5-HTP) Rubidium chloride (RbCl) Tryptophan

WHO-EM
Withdrawn from market
Clinical trials:
- Phase III
- Never to phase III

Categories: